ReviewEndocrine2004
Adverse neoplastic and cardiovascular outcomes of HRT: the validity of the evidence.
Review in Endocrine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 13 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The possibility that HRT may increase the risk of cancer, female cancers in particular, has been a general concern ever since HRT was first advocated in the mid-1950s. For cancer of the uterus that concern was vindicated when it was shown that unopposed estrogens greatly increase the risk. However, because HRT is undoubtedly effective in relieving menopausal symptoms, and because it was thought that HRT may reduce the risk of coronary heart disease, the use of estrogens in combination with progestins soon supplanted unopposed estrogen use (if less so among women who had undergone hysterectomies), in the belief, soon confirmed by epidemiological evidence, that combined therapy probably eliminates any increase in the risk of uterine cancer, or perhaps even reduces it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.